Pulmonary arterial hypertension (PAH) is a lethal syndrome characterized by obstruction of the pulmonary vasculature due (in part) to idiopathic hyper-proliferation of pulmonary arterial smooth muscle cells (PASMC). Preliminary data suggest that this proliferative diathesis relates to excessive mitochondrial fission caused by activation of dynamin related protein 1 (DRP-1). In this proposal we will define the molecular basis for dysregulation of fission in human PAH and explore the nature of the link between a mitochondrial fission-fusion cycle and the cell cycle. We also evaluate whether the requirement of these hyper-proliferative cells for high rates of mitochondrial fission presents an Achilles hee that can be therapeutically targeted. Experiments are performed in human PAH PASMC and lungs and in experimental models (induced by monocrotaline or SU5416 + hypoxia). Preliminary data indicate that human PAH PASMC have fragmented mitochondria, largely due to increased fission. We have developed metrics that use mitochondrial-targeted, photoactivated, green fluorescent protein (mito-paGFP) and 2-photon confocal microscopy to quantify mitochondrial fission. Increased fission in PAH appears to result from phosphorylation of DRP-1 at Serine 616 by the key mitotic regulatory kinase, Cyclin B1- CDK1, thus linking fission and mitosis. Elevated cytosolic calcium in PAH also promotes DRP-1-mediated fission by: a) activation of calmodulin kinase and b) calcineurin-mediated dephosphorylation of an inhibitory form of DRP- 1 (Phos-Ser637). Thus, increased activity of calcineurin, cyclin B1-CDK1 and DRP-1 promote fission and proliferation in human PAH PASMC;conversely, DRP-1 inhibition (via the small molecule inhibitor, mdivi-1, or siDRP-1) decreases PASMC proliferation and, in the case of mdivi-1, regresses PAH in vivo. Hypothesis: Pathologic DRP-1 activation increases fission and promotes excessive PASMC proliferation in PAH. Corollary: DRP-1 inhibition prevents cell cycle progression, causing G2-M phase arrest. Anti-fission therapies may constitute an antiproliferative therapy for PAH.
Aim 1) Are DRP-1 activation and fission required for the hyperproliferation of PASMC in human PAH? Aim 2) Does post-translational DRP-1 modification regulate PASMC proliferation in PAH? Aim 3) Does inhibition of mitochondrial fission have therapeutic benefit in experimental PAH? Innovation and Impact: This proposal is innovative in recognizing that """"""""mitochondrial checkpoints"""""""", related to DRP-1 activation and fission, regulate cell cycle progression. The concept that mitochondrial fission is tightly linked to cell cycle progression via shared regulatory kinases is also novel. The discovery that inhibiting DRP-1 (directly or by targeting its regulatory kinases) is anti-proliferative offers a new, """"""""anti-fission profusion"""""""", therapeutic paradigm for PAH. The translational potential of this proposal is enhanced by careful correlation of results in rodent PAH models with findings in human PAH lungs/cells from a well-characterized cohort. This is the first study to exploit PAH's reliance on rapid fission to devise novel anti-fission, anti-proliferative therapies for PAH.
Pulmonary arterial hypertension (PAH) is a disease of the lung's blood vessels caused in part by excessive rates of vascular growth, leading to vascular obstruction and this places a strain on the right heart, causing disability and a 15% annual death rate due to right heart failure. We identified a mitochondrial abnormality in human PAH smooth muscle cells that causes them to grow rapidly, contributing to the blockage. In PAH the mitochondrial network is fragmented, a process called fission. Excess fission reflects increased activity of an enzyme called dynamin related protein (DRP-1). Inhibiting DRP-1 slows cell growth and reduces experimental PAH. We will define the cause of increased fission in PAH and explore a link between fission and mitosis that relates to a shared regulatory kinase, CDK1. Increased fission may present an Achilles heel for rapidly growing cells. The therapeutic potential of anti-fission drugs is tested in human PAH tissues/cells and in rodent models.
|Prins, Kurt W; Rose, Lauren; Archer, Stephen L et al. (2018) Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension. Am J Respir Crit Care Med 197:1496-1499|
|Thenappan, Thenappan; Ormiston, Mark L; Ryan, John J et al. (2018) Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 360:j5492|
|Wijeratne, D Thiwanka; Lajkosz, Katherine; Brogly, Susan B et al. (2018) Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. Circ Cardiovasc Qual Outcomes 11:e003973|
|Tian, Lian; Potus, Francois; Wu, Danchen et al. (2018) Increased Drp1-Mediated Mitochondrial Fission Promotes Proliferation and Collagen Production by Right Ventricular Fibroblasts in Experimental Pulmonary Arterial Hypertension. Front Physiol 9:828|
|Chen, Kuang-Hueih; Dasgupta, Asish; Lin, Jianhui et al. (2018) Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications. Circulation 138:287-304|
|Prins, Kurt W; Archer, Stephen L; Pritzker, Marc et al. (2018) Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant 37:376-384|
|Xiong, Ping Yu; Potus, Francois; Chan, Winnie et al. (2018) Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension. Hypertension 71:34-55|
|Thenappan, Thenappan; Archer, Stephen L; Weir, E Kenneth (2017) Resistance over compliance describes right ventricular afterload better than resistance-compliance time: a friendly amendment. Pulm Circ 7:275|
|Selvam, Soundarya N; Casey, Lara J; Bowman, Mackenzie L et al. (2017) Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients. Blood Coagul Fibrinolysis 28:521-533|
|Archer, Stephen L (2017) Pyruvate Kinase and Warburg Metabolism in Pulmonary Arterial Hypertension: Uncoupled Glycolysis and the Cancer-Like Phenotype of Pulmonary Arterial Hypertension. Circulation 136:2486-2490|
Showing the most recent 10 out of 51 publications